- FSD Pharma has revealed it has submitted a clinical trial application to assess its Unbuzzd beverage in a planned Phase 1b clinical trial
- The trial will aim to test the safety and efficacy of Unbuzzd in healthy volunteers in an induced state of alcohol intoxication
- The clinical trial application is submitted for review by a human ethics review committee in Australia
- Shares of FSD Pharma are down 3.12 per cent to C$1.09 as of 11:34 am ET
FSD Pharma (CSE:HUGE) has officially submitted a clinical trial application to assess its Unbuzzd beverage in a planned Phase 1b clinical trial.
In a news release, the Toronto-based company stated the upcoming trial will test the safety and efficacy of Unbuzzd in healthy volunteers in an induced state of alcohol intoxication.
Unbuzzd is a dietary supplement product currently being developed for potential marketing in the United States. The beverage is a fortified oral liquid formula that includes natural ingredients and other food supplements with the potential to enhance cognition and replenish cofactors needed for alcohol metabolism.
The beverage has also been shown to accelerate the rate of alcohol metabolism within the body.
At present, the clinical trial application has been submitted for review by a human ethics review committee in Australia.
“This marks the culmination of several months of intense work by the FSD team and by our expert advisors, conceptualizing and designing this meaningful clinical trial to assess the safety and efficacy of this exciting product on people who drink alcohol,” Andrzej Chruscinski, vice president of scientific and clinical affairs at FSD Pharma, said in a news release.
FSD Pharma is focused on developing biotech solutions for treating neurodegenerative and metabolic disorders and alcohol misuse disorders.
Shares of FSD Pharma are down 3.12 per cent to C$1.09 as of 11:34 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the FSD Pharma Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.